Boston Scientific announces that the Synergy platinum-chromium coronary stent system is the first and only stent with bioabsorbable polymer coating that is FDA-approved for the treatment of coronary artery disease. The drug coating and the polymer – which holds the drug to the stent – are fully absorbed shortly after the drug completes elution at three months.
This stent platform is designed to promote more rapid endothelialization and better healing as a result of eliminating long-term polymer exposure. The bioabsorbable polymer coating on the outer surface is approximately four microns thick. In comparison, a human hair is about 70 microns thick.
Boston Scientific’s proprietary platinum-chromium alloy provides excellent visibility during coronary stenting. Platinum has over twice the density of iron or cobalt, resulting in enhanced visibility under fluoroscopy. This alloy combined with stent design allows for high radial and axial strength and low stent recoil††.
Creating a stent that gradually releases medicine without long term polymer exposure has been a research priority for scientists and clinicians. The Synergy stent demonstrated exceptional outcomes in the Evolve II Clinical Trial, the first successful U.S. pivotal trial of a bioabsorbable polymer technology. In the most complex patient population ever studied in a U.S. pivotal stent trial, the Synergy stent reported no definite stent thrombosis after 24 hours.
